Frank F, Fabrizi A P, Gaist G, Frank-Ricci R, Piazzi M, Spagnolli F
Division of Neurosurgery, Bellaria Hospital, Bologna, Italy.
Appl Neurophysiol. 1987;50(1-6):302-9. doi: 10.1159/000100731.
The authors report their series of 45 patients harboring inoperable, low-grade cerebral neoplasms, treated in the past 6 years with 125I stereotactic brachytherapy. The majority of these tumors were grade I and II astrocytomas and oligodendrogliomas (82.2%). A 2.6- to 6-year follow-up shows good results in 65.6% with reduction or disappearance of the lesions on CT images and good social reentry. Nine patients (23.7%) died prior to follow-up. Young patients (less than 40 years) responded well to interstitial radiotherapy, while patients over 40 with the same histological findings of low-grade tumors responded poorly to this type of treatment. Diffuse infiltrating cortico-subcortical tumors, optochiasmatic gliomas, hypothalamic and lower brainstem neoplasms do not respond satisfactorily to 125I radioisotope implantations.
作者报告了他们对45例患有无法手术切除的低度脑肿瘤患者的治疗情况，这些患者在过去6年中接受了碘-125立体定向近距离放射治疗。这些肿瘤大多数为I级和II级星形细胞瘤和少突胶质细胞瘤（82.2%）。2.6至6年的随访显示，65.6%的患者效果良好，CT图像上病变缩小或消失，且能很好地重新融入社会。9例患者（23.7%）在随访前死亡。年轻患者（40岁以下）对间质放疗反应良好，而40岁以上具有相同低度肿瘤组织学表现的患者对这种治疗反应较差。弥漫性浸润性皮质-皮质下肿瘤、视交叉胶质瘤、下丘脑和低位脑干肿瘤对碘-125放射性同位素植入治疗反应不令人满意。
